Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

BACKGROUND: Given the scale of the ongoing COVID-19 pandemic, the development of vaccines based on different platforms is essential, particularly in light of emerging viral variants, the absence of information on vaccine-induced immune durability, and potential paediatric use. We aimed to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chappell, Keith J, Mordant, Francesca L, Li, Zheyi, Wijesundara, Danushka K, Ellenberg, Paula, Lackenby, Julia A, Cheung, Stacey T M, Modhiran, Naphak, Avumegah, Michael S, Henderson, Christina L, Hoger, Kym, Griffin, Paul, Bennet, Jillian, Hensen, Luca, Zhang, Wuji, Nguyen, Thi H O, Marrero-Hernandez, Sara, Selva, Kevin J, Chung, Amy W, Tran, Mai H, Tapley, Peter, Barnes, James, Reading, Patrick C, Nicholson, Suellen, Corby, Stavroula, Holgate, Thomas, Wines, Bruce D, Hogarth, P Mark, Kedzierska, Katherine, Purcell, Damian F J, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R, Munro, Trent P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055208/
https://www.ncbi.nlm.nih.gov/pubmed/33887208
http://dx.doi.org/10.1016/S1473-3099(21)00200-0

Ejemplares similares

Ejemplares similares